Pulmonary Delivery Fact Sheet
Drug Delivery Into the Lung is One of the Fastest Growing, Yet Technically Challenging Areas of Pharmaceutical Development
Development of Pulmonary Product
When developing a pulmonary drug product, the first key decision will be whether the product should be a Liquid or Dry Powder formulation. This choice will be dependent on several factors including speed to clinic, solubility and stability profile of the API, and the target dose to
be delivered.
Drug product development includes two equally important aspects:
Formulation Development: Producing a stable dry powder or liquid formulation, with the correct physical properties for successful delivery, such as viscosity, for liquid formulations, or particle size for dry powder formulations.
Delivery Performance: Ensuring that the target delivered dose is achieved from the selected
device and that the aerodynamic performance will result in the deposition in the target region
of the lung.
Delivery to the Lung: Dry Powder Inhalers (DPI)
Successful development of a DPI dosage form requires a good understanding of the
physiochemical properties of the API, extensive testing of the dry powder formulation, and its’ performance when delivered from the selected device.
The key to the successful development of a DPI formulation is the development of formulated drug substance particles with the correct aerodynamic size for pulmonary delivery. At Upperton this is achieved through two basic approaches: Pharmaceutical Spray Drying and Jet Milling.
Pharmaceutical Spray Drying is one of the most flexible and versatile particle engineeringtechniques and Upperton has over twenty years of experience in developing formulations andspray drying processes to create microparticles with the correct aerodynamic properties for deeplung delivery.
Once optimised spray drying processing parameters have been defined, the Upperton spraydryers can produce kilo quantities of engineered microparticles that can be precision filled intocapsules or directly into a DPI.
Delivery to the Lung: Liquid Formulations
Many customers initially enter the clinic with a liquid formulation for delivery via a nebuliser. The use of a liquid formulation is often seen as a ‘quick’ route into clinic as it avoids the need for more extensive dry powder formulation development timelines.
Successful development of liquid (nebulised) formulations requires a thorough investigation into the properties of the API, the formulated liquid product and the performance of the formulation in the device.
Analytical Testing
Generating stability and performance data on both liquid and dry powder pulmonary dosage forms require significant know-how and technical capability. Meaningful and reproducible performance data is critical to successful product development.
Upperton has a range of analytical capabilities to support development activities, including particle size by laser diffraction, microscopy including scanning electron microscopy, aerodynamic particle size distribution by cascade impactor (NGI), emitted dose and content uniformity.
